SCHEMBL4090740

SCHEMBL4090740

CCOC(=O)N1CCN(c2nc(-c3ccc(OC(F)(F)F)cc3)nc3ccccc23)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.62
KMT2A Q03164 4/20 0.62
GBA1 P04062 7/20 0.61
TP53 P04637 3/20 0.55
KDM4E B2RXH2 2/20 0.55
MAPT P10636 2/20 0.55
RAB9A P51151 2/20 0.53
NPC1 O15118 1/20 0.53
HRH2 P25021 1/20 0.51
HRH1 P35367 1/20 0.51
POLB P06746 1/20 0.50
ADRB2 P07550 1/20 0.50
SIRT1 Q96EB6 1/20 0.50
USP2 O75604 1/20 0.49
ALDH1A1 P00352 1/20 0.49
LMNA P02545 1/20 0.49
HPGD P15428 1/20 0.49
MAPK1 P28482 1/20 0.49
CTNNB1 P35222 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4090457 0.85 ALDH1A1 (0.48) MEN1KMT2AGBA1KDM4EMAPT
SCHEMBL4095930 0.85 MEN1 (0.66) MEN1KMT2AGBA1TP53KDM4E
SCHEMBL4096171 0.85 MEN1 (0.67) MEN1KMT2AGBA1TP53KDM4E
SCHEMBL23948080 0.85 GBA1 (0.63) MEN1KMT2AGBA1TP53RAB9A
SCHEMBL4090419 0.83 GBA1 (0.68) MEN1KMT2AGBA1TP53KDM4E
SCHEMBL4084420 0.83 MEN1 (0.64) MEN1KMT2AGBA1TP53KDM4E
SCHEMBL4085184 0.81 ACP1 (0.69) MEN1KMT2AGBA1TP53MAPT
SCHEMBL4085133 0.81 MEN1 (0.64) MEN1KMT2AGBA1TP53KDM4E
SCHEMBL4090887 0.81 ACP1 (0.70) MEN1KMT2AGBA1TP53MAPT
SCHEMBL1084085 0.79 MEN1 (0.67) MEN1KMT2AGBA1TP53KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 MEN1 718/4885KMT2A 1424/4885GBA1 2059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.